Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)

• Status: Completed
• Trial end date: 2005-01-14
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the effectiveness of an approved drug in the early treatment of migraine while the pain is still mild.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Rizatriptan

Criteria

Inclusion Criteria:

• 6-month history of migraine

• Migraine attacks typically mild when they begin with 1-4 migraine attacks per month

Exclusion Criteria:

• Heart disease

• High blood pressure